Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William M Winston

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|February 9, 2002
Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1William M Winston, Christina Molodowitch, Craig P Hunter
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2007
Caenorhabditis elegans SID-2 is required for environmental RNA interferenceWilliam M Winston, Marie Sutherlin, Amanda J Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2014
Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor modelsKristan Meetze, Sylvie Vincent, Steven Tyler, et al.
Cancer Immunology Research|March 14, 2022
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor RegressionChristopher J Nirschl, Heather R Brodkin, Daniel J Hicklin, et al.
Molecular Cancer Therapeutics|May 22, 2015
23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal ToxicityTheresa Proia, Feng Jiang, Alisa Bell, et al.
Cancer Immunology Research|April 19, 2023
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor ImmunityChristopher J Nirschl, Heather R Brodkin, Celesztina Domonkos, et al.
Cancer Research|August 17, 2010
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signalingAilin Bai, Kristan Meetze, Nhi Y Vo, et al.
Cancer Treatment and Research Communications|July 17, 2021
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibodyKenna Shirasuna, Gerald Koelsch, Cynthia Seidel-Dugan, et al.
Cancer Immunology Research|February 13, 2026
WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike "Non-Alpha" MuteinsChristopher J Nirschl, Kulandayan K Subramanian, Heather R Brodkin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|February 9, 2002
Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1William M Winston, Christina Molodowitch, Craig P Hunter
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2007
Caenorhabditis elegans SID-2 is required for environmental RNA interferenceWilliam M Winston, Marie Sutherlin, Amanda J Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2014
Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor modelsKristan Meetze, Sylvie Vincent, Steven Tyler, et al.
Cancer Immunology Research|March 14, 2022
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor RegressionChristopher J Nirschl, Heather R Brodkin, Daniel J Hicklin, et al.
Molecular Cancer Therapeutics|May 22, 2015
23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal ToxicityTheresa Proia, Feng Jiang, Alisa Bell, et al.
Cancer Immunology Research|April 19, 2023
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor ImmunityChristopher J Nirschl, Heather R Brodkin, Celesztina Domonkos, et al.
Cancer Research|August 17, 2010
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signalingAilin Bai, Kristan Meetze, Nhi Y Vo, et al.
Cancer Treatment and Research Communications|July 17, 2021
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibodyKenna Shirasuna, Gerald Koelsch, Cynthia Seidel-Dugan, et al.
Cancer Immunology Research|February 13, 2026
WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike "Non-Alpha" MuteinsChristopher J Nirschl, Kulandayan K Subramanian, Heather R Brodkin, et al.
Pageof 1